This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
E7-LP35 vaccine showed significantly higher antitumor activity compared to E7-SP and E7-LP20 vaccines.
Why it matters
This research highlights the potential of combining cancer vaccines with immune checkpoint inhibitors to improve treatment outcomes. It may lead to more effective therapies for HPV-related cancers.
How the study worked
The study utilized mouse TC-1 tumor models to compare the antitumor activity of different flagellin-adjuvanted peptide vaccines.
What this study cannot tell us
The study was conducted in mouse models, which may not fully translate to human responses. Further research is needed to confirm these findings in clinical settings.
Read the original research
Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.
Translational cancer research, 11(6), 1595-1602
Citation
Lee, Hye Hwa; Hong, Seol Hee; Rhee, Joon Haeng; Lee, Shee Eun. (2022). Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.. Translational cancer research, 11(6), 1595-1602. https://doi.org/10.21037/tcr-21-2798